Nasal Drug Delivery on the Rise - What's Next for Pharma
Abstract: Nasal drug delivery has evolved from a niche modality used primarily for decongestants into a versatile and increasingly strategic route for administering biologics, vaccines, emergency medicines, and central nervous system (CNS) therapies. Its ability to enable rapid absorption, bypass first-pass metabolism, and, in some cases, provide direct access to the brain has positioned nasal delivery at the forefront of non-invasive pharmaceutical innovation. As the pipeline of nasal drug candidates continues to expand—driven by advances in formulation science, device engineering, and digital technologies—developers face growing complexity related to stability, patient variability, regulatory requirements, and scalability. Strategic reliance on specialized development partners is accelerating progress, particularly for emerging modalities such as nose-to-brain and powder-based delivery systems. With continued investment and technological innovation, nasal drug delivery is poised to become a cornerstone of patient-centric, next-generation therapeutics.